P-glycoprotein (P-gp), an ABC efflux transporter, is highly expressed at the blood brain barrier (BBB). Recently, P-gp has been shown to transport amyloid-2, a protein which accumulates in the brain extracellular fluid in patients with Alzheimer's disease (AD). In sporadic, nonfamilial AD, amyloid-2 accumulates in the brain due to its reduced elimination and not due to its increased production. Therefore, we have hypothesized that the activity of P-gp, which mediates amyloid-2 clearance, is compromised at the BBB in AD patients. We will test this hypothesis by measuring P-gp activity at the BBB in mild-to-moderate AD patients and age-matched cognitively normal volunteers using a noninvasive positron emission tomography (PET) technique recently developed in our laboratories. The importance of P-gp in the clearance of amyloid-2 from the brain creates an exciting therapeutic opportunity to treat AD. P-gp is an inducible transporter and several, well-established approved drugs (e.g. rifampin), can induce P-gp activity. Therefore, our aim will be: To compare P-gp activity at the BBB in Alzheimer patients and in age-matched cognitively normal volunteers (controls), using the non-invasive technology, positron emission tomography (PET). Our studies will utilize an innovative, noninvasive PET imaging technique, developed by our laboratories, to measure P-gp activity at the BBB of patients with AD and age-matched cognitively normal volunteers. The logical progression of our studies from published data to in vivo studies in AD patients will unequivocally determine if P-gp activity is compromised in AD. These proposed studies have the potential to result in identification of P-gp as a novel therapeutic target for the treatment of AD, a disease for which no effective therapy exists.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Exploratory/Developmental Grants Phase II (R33)
Project #
Application #
Study Section
Clinical Neuroscience and Disease Study Section (CND)
Program Officer
Petanceska, Suzana
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
Schools of Pharmacy
United States
Zip Code
Huang, Jian; O'Sullivan, Finbarr (2014) An analysis of whole body tracer kinetics in dynamic PET studies with application to image-based blood input function extraction. IEEE Trans Med Imaging 33:1093-108
Deo, Anand K; Borson, Soo; Link, Jeanne M et al. (2014) Activity of P-Glycoprotein, a ?-Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease. J Nucl Med 55:1106-11
Zolnerciks, Joseph K; Booth-Genthe, Catherine L; Gupta, Anshul et al. (2011) Substrate- and species-dependent inhibition of P-glycoprotein-mediated transport: implications for predicting in vivo drug interactions. J Pharm Sci 100:3055-3061
Eyal, S; Ke, B; Muzi, M et al. (2010) Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography. Clin Pharmacol Ther 87:579-85
Endres, Christopher J; Endres, Michael G; Unadkat, Jashvant D (2009) Interplay of drug metabolism and transport: a real phenomenon or an artifact of the site of measurement? Mol Pharm 6:1756-65
Eyal, Sara; Hsiao, Peng; Unadkat, Jashvant D (2009) Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ther 123:80-104
Unadkat, Jashvant D; Chung, Francisco; Sasongko, Lucy et al. (2008) Rapid solid-phase extraction method to quantify [(11)C]-verapamil, and its [(11)C]-metabolites, in human and macaque plasma. Nucl Med Biol 35:911-7